【researchmap】
https://researchmap.jp/read0162114

1. 1.Ohta S, Misawa A, Chaw Kyi-Tha-Thu, et al, Melanoma antigens recognized by T cells and their use for immunotherapy. Exp Dermatol, 32:297, 2023
2. 2. Katoh Y, Yaguchi T, Kubo A, et al, Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. J Immunother Cancer, 10:e004616, 2022
3. 3. Nakajima T, Kadowaki S, Minashi K, et al, Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Can Res, 27:1029, 2021
4. 4. Kinoshita T, Sayem MA, Yaguchi T, et al, Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors. Cancer Sci, 112:1390, 2021
5. 5. Kawakami Y, Ohta S, Sayem MA, et al, Immune-resistant mechanisms in cancer immunotherapy, Int J Clin Oncol. 25(5):810, 2020
6. 6. Mlecnik B, Bifulco C, Bindea G, et al, Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. J Clin Oncol, 38:3638, 2020
7. 7. Tanoue T, Morita S, Plichta DR, et al, A defined consortium of human gut commensals induces CD8 T cells and modulates host microbial and cancer immunity. Nature, 565:600, 2019
8. 8. Pagès F, Mlecnik B, Marliot F, et al, International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, 391:2128, 2018
9. 9. Yaguchi T, Kobayashi A, Inozume T, et al. Human PBMC transferred murine MHC class I/II deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol. 14:1, 2017
10. 10. Kinoshita T, Muramatsu R, Fujita T, et al. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann Oncol. 27:2117, 2016
11. 11. Yaguchi T, Goto Y, Kido K, et al, Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol, 189:2110,2012
12. 12. Iwata-Kajihara T, Sumimoto H, Kawamura N, et al. Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors. J Immunol. 187:27, 2011
13. 13. Ueda R, Ohkusu-Tsukada K, Fusaki N, et al. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer. 126:919,2010
14. 14. Kudo-Saito C, Shirako H, Takeuchi T, et al. Cancer metastasis is accelerated through immunosuppression during EMT of cancer cell. Cancer Cell, 16:195, 2009
15. 15. Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocytes' Fcγ receptor balance toward inhibitory Fc γ RIIB in immune thrombocytopenic purpura. J Clin Invest. 118: 2939, 2008
16. 16. Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF-MAPK signaling pathway is essential for cancer immune evasion in human melanoma cells. J Exp Med, 203:1651,2006
17. 17. Kuwana M, Matsuura E, Kobayashi K, et al. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 105:1552,2005
18. 18. Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet. 364:603,2004
19. 19. Sumimoto H, Miyagishi M, Miyoshi H, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 23: 6031,2004
20. 20. Ishikawa T, Fujita T, Suzuki Y, et al. Tumor-specific Immunological Recognition of Frameshift-mutated Peptides in Colon Cancer with Microsatellite Instability. Cancer Res. 63:5564, 2003
21. 21. Toda M, Iizuka Y, Kawase T, et al. Immuno-Viral Therapy of Brain Tumors by Combination of Viral Therapy with Cancer Vaccination Using a Replication-Conditional HSV. Cancer Gene Ther.9:356, 2002
22. 22. Rosenberg SA, Yang J, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med, 4:321, 1998
23. 23. Parkhurst MR, Salgaller ML, Southwood S, et al.  Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol. 157:2539,1996
24. 24. Robbins PF, El-Gamil M, Li YF, et al. A mutated b-catenin gene encodes a melanoma - specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 183:1185, 1996.
25. 25. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA, 91:6458, 1994.
26. 26. Kawakami Y, Eliyahu S, Delgado CH, et al, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad SciUSA, 91:3515, 1994